Pathology: mML - L1 - BRAF mutant; mML - L1 - BRAF wild;
mML - L1 - BRAF mutant | mML - L1 - BRAF wild | ||
IMspire-150 (BRAF mutant), 2020 | IMspire-170, 2020 | ||
atezolizumab plus SoC | 1 | T1 | |
atezolizumab plus cometinib | 1 | T1 | |
placebo plus SoC | 0 | T0 | |
pembrolizumab alone | 0 | T0 |